Deutsche Bank Aktiengesellschaft Lowers Waters (NYSE:WAT) Price Target to $330.00

Waters (NYSE:WAT) had its price objective reduced by equities research analysts at Deutsche Bank Aktiengesellschaft from $370.00 to $330.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “hold” rating on the medical instruments supplier’s stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential upside of 9.76% from the company’s previous close.

WAT has been the subject of several other reports. Morgan Stanley lowered their price objective on Waters from $423.00 to $350.00 and set an “equal weight” rating for the company in a research report on Sunday, February 22nd. Barclays initiated coverage on Waters in a research note on Tuesday, February 10th. They set an “overweight” rating and a $400.00 target price for the company. Wall Street Zen downgraded Waters from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Guggenheim reiterated a “buy” rating and issued a $440.00 price target on shares of Waters in a research note on Tuesday, February 10th. Finally, William Blair began coverage on shares of Waters in a report on Monday, January 5th. They set an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $394.63.

Waters Stock Down 0.6%

Shares of NYSE:WAT opened at $300.65 on Wednesday. Waters has a fifty-two week low of $275.05 and a fifty-two week high of $414.15. The firm’s 50 day moving average price is $335.21 and its 200 day moving average price is $350.84. The company has a quick ratio of 1.27, a current ratio of 1.73 and a debt-to-equity ratio of 0.37. The stock has a market cap of $29.49 billion, a price-to-earnings ratio of 27.92, a price-to-earnings-growth ratio of 2.08 and a beta of 1.20.

Waters (NYSE:WAT) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, topping the consensus estimate of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The company had revenue of $932.36 million during the quarter, compared to analysts’ expectations of $928.17 million. During the same quarter in the previous year, the business posted $4.10 EPS. The firm’s revenue was up 6.9% on a year-over-year basis. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. As a group, equities research analysts predict that Waters will post 12.86 earnings per share for the current fiscal year.

Insider Transactions at Waters

In other news, Director Wei Jiang purchased 500 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were purchased at an average price of $289.46 per share, for a total transaction of $144,730.00. Following the purchase, the director directly owned 3,441 shares of the company’s stock, valued at $996,031.86. This represents a 17.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.63% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Waters

Several large investors have recently modified their holdings of WAT. Root Financial Partners LLC purchased a new position in Waters during the 3rd quarter worth $26,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Waters in the third quarter valued at about $26,000. Zions Bancorporation National Association UT boosted its stake in shares of Waters by 121.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 40 shares during the period. SHP Wealth Management purchased a new position in shares of Waters during the fourth quarter worth about $32,000. Finally, DV Equities LLC purchased a new position in shares of Waters during the fourth quarter worth about $32,000. 94.01% of the stock is owned by institutional investors and hedge funds.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.